RESEARCH ARTICLE · BMJ Open · 2016

Vulnerability for new episodes in recurrent major depressive disorder: protocol for the longitudinal DELTA-neuroimaging cohort study

Roel J. T. Mocking, Caroline Astrid Figueroa, Maria M. Rive, Hanneke Geugies, Michelle N. Servaas, Johanna Assies, Maarten W.J. Koeter, Frédéric Maxime Vaz, Marieke Wichers, Jan P. van Straalen, Rudi De Raedt, Claudi Bockting, Catherine J. Harmer, Aart H. Schene, Henricus Gerardus Ruhé

Read original paper ↗

See where this research leads.

A citation map has not been saved for this paper yet.

Open in your workspace →Open your workspace to prepare the citation network.

The paper record is available below. Preparing a network uses the existing account and source-allowance controls.

Papers that cite this work

No saved citation network is available; this does not mean the paper has no citations.

The evidence behind the map

Publication record

Research article.

Abstract

INTRODUCTION: Major depressive disorder (MDD) is widely prevalent and severely disabling, mainly due to its recurrent nature. A better understanding of the mechanisms underlying MDD-recurrence may help to identify high-risk patients and to improve the preventive treatment they need. MDD-recurrence has been considered from various levels of perspective including symptomatology, affective neuropsychology, brain circuitry and endocrinology/metabolism. However, MDD-recurrence understanding is limited, because these perspectives have been studied mainly in isolation, cross-sectionally in depressed patients. Therefore, we aim at improving MDD-recurrence understanding by studying these four selected perspectives in combination and prospectively during remission. METHODS AND ANALYSIS: In a cohort design, we will include 60 remitted, unipolar, unmedicated, recurrent MDD-participants (35-65 years) with ≥ 2 MDD-episodes. At baseline, we will compare the MDD-participants with 40 matched controls. Subsequently, we will follow-up the MDD-participants for 2.5 years while monitoring recurrences. We will invite participants with a recurrence to repeat baseline measurements, together with matched remitted MDD-participants. Measurements include questionnaires, sad mood-induction, lifestyle/diet, 3 T structural (T1-weighted and diffusion tensor imaging) and blood-oxygen-level-dependent functional MRI (fMRI) and MR-spectroscopy. fMRI focusses on resting state, reward/aversive-related learning and emotion regulation. With affective neuropsychological tasks we will test emotional processing. Moreover, we will assess endocrinology (salivary hypothalamic-pituitary-adrenal-axis cortisol and dehydroepiandrosterone-sulfate) and metabolism (metabolomics including polyunsaturated fatty acids), and store blood for, for example, inflammation analyses, genomics and proteomics. Finally, we will perform repeated momentary daily assessments using experience sampling methods at baseline. We will integrate measures to test: (1) differences between MDD-participants and controls; (2) associations of baseline measures with retro/prospective recurrence-rates; and (3) repeated measures changes during follow-up recurrence. This data set will allow us to study different predictors of recurrence in combination. ETHICS AND DISSEMINATION: The local ethics committee approved this study (AMC-METC-Nr.:11/050). We will submit results for publication in peer-reviewed journals and presentation at (inter)national scientific meetings. TRIAL REGISTRATION NUMBER: NTR3768.

Coverage and freshness

Citation coverage has not been established for this paper.

Counts describe saved source records; repository versions may appear separately. A completed source query is not a complete or live citation census. A citation does not prove endorsement or research quality. Counts depend on publication age and index coverage. Colors identify research areas; positions are for readability.

Source: Saved OpenAlex scholarly metadata. Visits to this public page do not acquire new provider data.

Report a correction